LUNG (Pulmonx) Total Equity: $45.76 Mil (As of Mar. 2026)


LUNG Pulmonx Corp LUNG
49 GF Score
Price $1.44
GF Value $7.13
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Pulmonx Total Equity?

Pulmonx LUNG +9.54% 49 Total Equity is $45.76 Mil as of Mar. 2026. GuruFocus rates LUNG with a GF Score™ of 49/100 and a GF Value™ of $7.13 (Possible Value Trap). The stock has 6 warning signs investors should review.

Pulmonx's total equity for the quarter that ended in Mar. 2026 was $45.76 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Pulmonx Total Equity Historical Data

* Premium members only.

The historical data trend for Pulmonx's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulmonx Total Equity Chart

Pulmonx Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 193.24 154.01 118.32 85.81 54.12

Pulmonx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 77.67 69.09 60.03 54.12 45.76
LUNG
49GF Score
Pulmonx Corp LUNG
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pulmonx Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Pulmonx's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=129.291-75.175
=54.12

Pulmonx's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=119.966-74.205
=45.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $45.76 Mil mean?
Pulmonx (LUNG) has a Total Equity of $45.76 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Pulmonx and its competitors.
Is Pulmonx's Total Equity too high?
Pulmonx's current Total Equity is $45.76 Mil. Overall, Pulmonx has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pulmonx's Total Equity compare to MDAI and QTI?
Pulmonx's Total Equity of $45.76 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Pulmonx and its competitors. Pulmonx's current Total Equity is $45.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulmonx stock overvalued right now?
Based on GuruFocus' analysis, Pulmonx (LUNG) is currently considered Possible Value Trap. The stock's GF Value™ is $7.13, compared to a current price of $1.44 — trading 79.9% below its estimated fair value. The current Total Equity is $45.76 Mil. Pulmonx's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Pulmonx (LUNG), the current Total Equity is $45.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pulmonx (LUNG) Overvalued in 2026?

Based on GuruFocus' analysis, Pulmonx stock appears to be undervalued. The current stock price of $1.44 is trading 79.9% below its estimated GF Value™ of $7.13. GuruFocus considers Pulmonx to be Possible Value Trap.

Key valuation signals for LUNG:

  • Total Equity: $45.76 Mil
  • GF Value™: $7.13 vs. price of $1.44 (79.9% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the LUNG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pulmonx Business Description

Other Exchanges 4NI:Germany
Address 700 Chesapeake Drive, Redwood, CA, USA, 94063
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
49GF Score

Get the complete analysis for LUNG

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.44
Price
$7.13
GF Value